Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Central IRBs to Speed Up
June 12, 2006
- BUSINESS NEWS IN BRIEF
June 12, 2006
- JMA to Use Network to Activate
June 12, 2006
- Taiyo Pharm.: Sales Rise 16.6% to \29,191 Mil.
June 12, 2006
- R&D NEWS IN BRIEF
June 12, 2006
- Sawai: Sales Up 14.3% to \26,616 Million
June 12, 2006
- BrainLAB's Radiotherapy Equipment Introduced
June 12, 2006
- Towa Sees Setback Due to Increasing Competition
June 12, 2006
- NEW PRODUCTS
June 12, 2006
- Nichi-iko Revises Its Business Forecast Upward
June 12, 2006
- MEDICAL DEVICE NEWS IN BRIEF
June 12, 2006
- Novartis' Smoking Cessation
June 12, 2006
- 52 Companies Utilized Contract Training for MRs in FY2005: MREAC
June 12, 2006
- SURVEY an article
June 12, 2006
- JAPIC Regulatory Affairs Seminar
June 12, 2006
- OPINION
June 12, 2006
- NHO to Cut Number of Drugs
June 12, 2006
- Wakomoto Resumes GE Drug Development in Field of Ophthalmology
June 12, 2006
- SELF-MEDICATION NEWS IN BRIEF
June 12, 2006
- Pfizer Japan Aims for Top
June 12, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…